Journal Watch · Arthritis & Rheumatology · 2026

Per- and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data From the Osteoarthritis Initiative.

We observed no other consistent associations between PFAS and either outcome.<h4>Conclusion</h4>We observed possible associations of PFDA and PFNA serum concentrations with symptomatic HOA incidence, but we otherwise found no consistent evidence that greater PFAS concentrations relate to a greater chance of developing HOA incidence or progression.

Driban JB, Rokoff LB, Lu B et al.Arthritis & Rheumatology3 min readPharma relevance 30/100

DOI: 10.1002/art.70026PMID: 41429602Study type: cohort / observational clinical study

TL;DR

We observed no other consistent associations between PFAS and either outcome.<h4>Conclusion</h4>We observed possible associations of PFDA and PFNA serum concentrations with symptomatic HOA incidence, but we otherwise found no consistent evidence that greater PFAS concentrations relate to a greater chance of developing HOA incidence or progression.

Key findings

  • We observed no other consistent associations between PFAS and either outcome.<h4>Conclusion</h4>We observed possible associations of PFDA and PFNA serum concentrations with symptomatic HOA incidence, but we otherwise found no consistent evidence that greater PFAS concentrations relate to a greater chance of developing HOA incidence or progression.

Numbers at a glance (from the abstract)

n = 1,87858%95%OR 0.94

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Participants with higher perfluorodecanoic acid (PFDA) and perfluorononanoic acid (PFNA; continuous variables) had greater odds of incident symptomatic HOA (odds ratio [OR] [95% confidence interval (CI)] per interquartile range increment: PFDA 1.12 [1.05-1.20]; PFNA 1.07 [1.00-1.13]), but associations were not monotonic when these PFAS were represented in quartiles. Participants with higher perfluorohexane sulfonic acid had lower odds of incident HOA (eg, OR 0.94 [95% CI 0.88-1.00] per interquartile range increment).

Full abstract (original)

Background: <h4>Objective</h4>To explore whether biologic levels of specific per- and polyfluoroalkyl substances (PFAS) and a mixture of PFAS-reflecting the overall effect and accounting for correlations among PFAS-relate to incident hand osteoarthritis (HOA) and progression.<h4>Methods</h4>Among a case-cohort sample from the Osteoarthritis Initiative (n = 1,878), we examined associations of eight PFAS in serum with odds of developing over the subsequent 4 years (1) symptomatic HOA and (2) an increased number of joints with radiographic osteoarthritis (Kellgren-Lawrence ≥2; yes/no). We used weighted logistic regression to assess single PFAS (continuous and quartiles) and quantile g-computation to assess the PFAS mixture in relation to our primary outcomes.<h4>Results</h4>Participants were primarily female (58%) and on average aged 62 years and overweight (mean body mass index = 28.6 kg/m<sup>2</sup>).

What they did: Participants with higher perfluorodecanoic acid (PFDA) and perfluorononanoic acid (PFNA; continuous variables) had greater odds of incident symptomatic HOA (odds ratio [OR] [95% confidence interval (CI)] per interquartile range increment: PFDA 1.12 [1.05-1.20]; PFNA 1.07 [1.00-1.13]), but associations were not monotonic when these PFAS were represented in quartiles. Participants with higher perfluorohexane sulfonic acid had lower odds of incident HOA (eg, OR 0.94 [95% CI 0.88-1.00] per interquartile range increment).

Results & conclusions: We observed no other consistent associations between PFAS and either outcome.<h4>Conclusion</h4>We observed possible associations of PFDA and PFNA serum concentrations with symptomatic HOA incidence, but we otherwise found no consistent evidence that greater PFAS concentrations relate to a greater chance of developing HOA incidence or progression.

Abstract © the authors / Arthritis & Rheumatology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/art.70026 · PubMed 41429602.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Arthritis & Rheumatology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Arthritis & Rheumatology study find?

We observed no other consistent associations between PFAS and either outcome.<h4>Conclusion</h4>We observed possible associations of PFDA and PFNA serum concentrations with symptomatic HOA incidence, but we otherwise found no consistent evidence that greater PFAS concentrations relate to a greater chance of developing HOA incidence or progression.

What type of study is this?

It is a cohort / observational clinical study, published in Arthritis & Rheumatology in 2026. Participants with higher perfluorodecanoic acid (PFDA) and perfluorononanoic acid (PFNA; continuous variables) had greater odds of incident symptomatic HOA (odds ratio [OR] [95% confidence interval (CI)] per interquartile range increment: PFDA 1.12 [1.05-1.20]; PFNA 1.07 [1.00-1.13]), but associations were not monotonic when these PFAS were represented in quartiles.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/art.70026. PubMed ID: 41429602. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Driban JB, Rokoff LB, Lu B et al.. Per- and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data From the Osteoarthritis Initiative.. Arthritis & Rheumatology (2026). DOI: 10.1002/art.70026.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/per-and-polyfluoroalkyl-substances-and-hand-osteoarthritis-data-from-the-t70026/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides